PLAINSBORO, N.J., May 3, 2009 (GlobeNewswire via COMTEX News Network) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) is featuring the CUSA NXT(TM) ultrasonic tissue ablation system at the 2009 American Association of Neurological Surgeons Annual Meeting in San Diego, California, May 2-6, 2009. The CUSA NXT(TM) ultrasonic tissue ablation system provides powerful and precise soft tissue removal with built-in irrigation and aspiration, and marks a significant new addition to Integra's market-leading CUSA(R) portfolio. Integra's CUSA NXT(TM) system is the result of Integra's extensive ultrasonic tissue ablation engineering expertise and development efforts. The CUSA NXT(TM) system has received FDA clearance in the United States and CE Mark Certification in the European Union.

The CUSA NXT(TM) system features revolutionary NXT Digital Architecture(TM), which delivers consistent tissue removal performance, enables advanced aspiration, and offers an intuitive touch-screen user interface. The new user interface is easy to understand, provides clear visual feedback, and gives clinicians quick access to system information. NXT Digital Architecture(TM) also provides an expandable platform, enabling future tissue ablation capabilities and clinical applications.

"The CUSA NXT(TM) system is a truly innovative advance in ultrasonic tissue ablation technology that further separates us from the competition. The CUSA NXT(TM) system confirms Integra's commitment to leadership in ultrasonic tissue ablation," said Chris Thatcher, President of Integra NeuroSciences.

With the growth in intra-operative imaging, including new magnetic resonance imaging (MRI) surgical suites that allow the surgeon to confirm complete tumor removal during the procedure, the CUSA NXT(TM) system was designed to work in the vicinity of high magnetic fields and allow rapid shutdown and restart when necessary.

"The CUSA NXT(TM) ultrasonic tissue ablation system gives surgeons the power, precision, and control needed for selective dissection of soft and hard tissue, including bone," stated Christopher von Jako, Vice President of Marketing for Integra NeuroSciences. "The NXT Digital Architecture(TM) reflects Integra's commitment to deliver products and support that help our customers Operate with Confidence(TM)."

Over 2,000 centers worldwide use CUSA(R) technology for a variety of tissue ablation procedures, including the removal of brain and abdominal tumors. The total U.S. market for ultrasonic tissue ablation products is over $60 million, according to Medtech Insight's U.S. Markets for Neurosurgical and Neurointerventional Surgical Products in December 2006.

Integra currently offers a diverse line of CUSA(R) tissue ablation products, including the CUSA NXT(TM), CUSA EXcel(R), CUSA(R) Selector(R), and CUSA(R) Dissectron(R) systems. The CUSA(R) systems are sold by the Integra NeuroSciences sales organization. Integra NeuroSciences is a leading provider of implants, devices, instruments, and systems used in neurosurgery, neuromonitoring, neuro-trauma, and related neurocritical care. The Integra NeuroSciences direct sales force is the largest neurosurgical sales force in the United States. Integra also has direct sales channels in Europe, Canada, Australia, and New Zealand. In all other markets, Integra NeuroSciences products are sold through a network of distributors.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of clinically relevant, innovative, and cost-effective surgical implants and medical instruments. Integra's products, used primarily in neurosurgery, orthopedics and general surgery, are used to treat millions of patients every year. The company's headquarters are in Plainsboro, New Jersey, and it has research and manufacturing facilities throughout the world. For more information visit www.Integra-LS.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of Integra products. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in section IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2008 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

IART-P

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation
          Gianna Sabella, Director of Corporate Communications
          (609) 936-2389 
          gsabella@integra-LS.com

(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.

News Provided by COMTEX